Skip to main content
. 2011 Sep;20(121):201–207. doi: 10.1183/09059180.00002011

Figure 3.

Figure 3.

Change in forced vital capacity (FVC) % predicted (% pred) in study 004 and study 006 comparing pirfenidone or placebo in patients with idiopathic pulmonary fibrosis [29, 35]. ▪: study 004 pirfenidone 2,403 mg·day−1; •: study 006 pirfenidone 2,403 mg·day−1; ▴: study 006 placebo; ▾: study 004 placebo.